Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aimovig in CGRP and Cilostazol Induced Migraine Models
NCT04452929Unknown
- Sponsor
- Dansk Hovedpinecenter
- Start
- Jul 2020
- Primary completion
- Feb 2022
- Countries
- 1
01
Overview
Randomised, double-blind trial of erenumab in migraine, sponsored by Dansk Hovedpinecenter. Primary endpoint: Incidence of migraine-like attack at 12 hours. Status: unknown.
02
Drugs
erenumab
03
Conditions
migraine
Beyond the preview
Go deeper on NCT04452929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04452929.